BAYN.DE - Bayer Aktiengesellschaft
| Previous close | 52.28 |
| Open | 52.20 |
| Bid | 52.10 x 28400 |
| Ask | 52.11 x 2100 |
| Day's range | 52.05 - 52.59 |
| 52-week range | 46.70 - 66.73 |
| Volume | |
| Avg. volume | 2,238,983 |
| Market cap | 51.214B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | 16.65 |
| EPS (TTM) | 3.13 |
| Earnings date | 08 Aug 2023 |
| Forward dividend & yield | 2.40 (4.62%) |
| Ex-dividend date | 02 May 2023 |
| 1y target est | 73.10 |
ZacksBayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
ZacksPharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
ZacksBayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
- Zacks
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
- Zacks
Bayer (BAYRY) Q1 Earnings Beat, Crop Science Sales Decline
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
ZacksRegeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
- Reuters SG
UPDATE 1-Bayer investors re-elect Winkeljohann as board chairman
Bayer Chairman Norbert Winkeljohann on Friday comfortably won a re-election vote at the drugmaker's annual shareholder meeting with an approval rate of 79.6%. Germany's three biggest asset management groups earlier said they would not vote for his renewed term at Bayer because of his numerous other board commitments. An ouster of Winkeljohann, who won wide investor praise for securing former Roche executive Bill Anderson as Bayer's CEO-designate, would have sparked upheaval at the healthcare and agriculture group, which has attracted activist shareholders and is facing costly litigation.
ReutersBayer chair wins backing from major shareholder advisory firms
Bayer Chairman Norbert Winkeljohann has won backing for his re-election from a pair of major shareholder advisory firms despite criticism from two German investment groups for his numerous board commitments. In separate reports made available to Reuters, Institutional Shareholder Services (ISS) and Glass Lewis said they were backing Winkeljohann when his term comes up for a renewal vote at the drug company's April 28 annual shareholder meeting. German mutual funds groups DWS and Union Investment last month condemned the multiple board commitments of the Bayer chairman, adding to upheaval at the company which is the target of activist investors in the run-up to a change of chief executive on June 1.
ReutersIn listening mode, new Bayer CEO keeps 'open mind' on company split
Incoming Bayer chief executive Bill Anderson says he is keeping an open mind on whether to break up the company into smaller pieces, as some fidgety investors want. Anderson, who takes over the nearly 160-year-old German drugmaker at the start of June after calls from investors to remove his predecessor, says he will spend the next two months "listening" and sees no consensus on the issue so far. The 56-year-old chemicals engineer from the U.S., brought over from Swiss rival Roche, begins at a testing time, weighed down by lawsuits claiming Bayer's weed-killer causes cancer and pressure from investors demanding major change.
ReutersBayer defeats Merck in lawsuit over talc liabilities
(Reuters) -A Delaware judge on Monday dismissed Merck & Co's lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck's consumer care business in 2014. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement "clearly and unambiguously" left Merck liable for claims related to products, including Dr. Scholl's foot powder, sold before the transaction closed. Merck claimed that its liability ended on Oct. 1, 2021, seven years after the transaction closed, and sued Bayer after the German company refused to assume liability.
- Reuters SG
CORRECTED-Shareholder Temasek backs re-election of Bayer supervisory board chair -WiWo
Shareholders are due to vote on another term for Norbert Winkeljohann at Bayer's annual general meeting on April 28. The drugmaker has been the target of activist investors in the run-up to a change of CEO on June 1.
ReutersBayer's pharma chief hopes EU takes time to improve drug rules reform
The European Union's decision to postpone rule changes for the pharmaceutical industry could open the way for a rethink of a decision to cut intellectual drug property protection, the head of Bayer's pharmaceuticals division said. The European Commission said this week that the publication of a first draft of a planned revision of drug legislation in the bloc would be "slightly later" than March 29, as initially planned. A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection.
ZacksBayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak
Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.
ReutersBayer says investor Jeff Ubben joins its independent sustainability council
FRANKFURT (Reuters) -Bayer has appointed Jeff Ubben to the drugmaker's independent sustainability council, in a sign that the activist investor will be given a say at the embattled group. The Germany company said in a statement on Monday that Ubben would be one of three new entrants to the nine-member council, which meets with members of Bayer's management board twice a year. Bayer's shares have been weighed down by litigation over its Roundup weedkiller and by its diversified structure, drawing investors' criticism.
ReutersBrazil Supreme Court rules Bayer must return $252 million in GMO soy royalties
Germany's Bayer has been ordered by Brazil's Supreme Court to return to Brazilian soybean farmers the royalties they were charged for a GMO soybean seed, the Mato Grosso farmer lobby Aprosoja-MT said in a statement on Friday. The Feb. 13 ruling by Supreme Court Justice Nunes Marques relates to a GMO technology commercially known as Intacta RR2 Pro, created by Monsanto, which was later acquired by Germany's Bayer.
ZacksPharma Stock Roundup: AZN, ABBV Mixed Q4 Results, BAYRY's New CEO
AstraZeneca (AZN) and AbbVie (ABBV) report fourth-quarter results. Roche (RHHBY) and J&J (JNJ) announce positive data from studies on pipeline candidates for rare diseases.
ZacksRegeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
ReutersAnalysis: Bayer's new CEO has a full in-tray as investors push for change
Bayer's incoming CEO is inheriting a full in-tray from his predecessor: Thousands of lawsuits claiming its weedkiller causes cancer, an underwhelming drug development pipeline and disgruntled investors looking for major change. Top investors, including mutual funds group Deka, are among those to have complained that Bayer's sagging shares have been burdened by a lack of trust in the company's leadership, with others reckoning one easy fix would be to separate the healthcare and agricultural businesses. Bayer on Wednesday named long-time Roche executive Bill Anderson for the top job after months of shareholder pressure to remove embattled CEO Werner Baumann, who had previously said he would hold on until the end of his current term in April 2024.
ReutersGerman union opposes Bayer split after CEO departure - taz newspaper
BERLIN (Reuters) -Germany's IGBCE union opposes any splitting-up of Bayer after the departure of its chief executive and warned that the company should not bow to pressure from hedge fund activism, taz newspaper reported on Thursday. "From the point of view of the employees, Bayer with its three pillars is perfectly positioned for the challenges of the future," said IGBCE executive board member Francesco Grioli, who is also a member of the supervisory board at Bayer. Bayer announced on Wednesday that it was replacing its CEO early, recruiting the former head of Roche's pharmaceuticals business, as investor criticism over the company’s lacklustre share price grew.
ReutersBayer hopes for swift resolution to Russia sunseed shipment delay
Germany's Bayer said on Wednesday it was continuing to supply agricultural products to Russia and hoped for a swift resolution to what it called a technical delay in the country's sunflower seed imports. The Izvestia newspaper said on Monday that Western seed producers had suspended sunflower seed shipments to Russia and paused customers' bids for purchases, citing letters sent by Bayer, Swiss agrochemicals group Syngenta and seed firm Nuseed.
ReutersActivist investor rallies Bayer shareholders as pressure on CEO mounts -sources
FRANKFURT (Reuters) -Bayer investor Jeff Ubben has contacted fellow shareholders in the German group, investors and sources familiar with the matter told Reuters, in an apparent attempt to rally support for big changes at the drugs-to-pesticides company. The campaign increases the pressure on non-executive Chairman Norbert Winkeljohann, who has faced calls from large shareholders for the swift replacement of Chief Executive Werner Baumann, who engineered Bayer's troubled Monsanto takeover. The approaches come after Ubben's activist investment fund Inclusive Capital Partners said last month it had bought a 0.83% stake in Bayer.
ZacksRegeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
ZacksHere's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ReutersBayer under investor pressure to speed up CEO changeover
A top-10 shareholder in Bayer on Tuesday called on the group's supervisory board to replace chief executive Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker's sagging share price. Despite recent improvements in the company's agriculture business and drug development prospects, Bayer shares have been weighed down by litigation related to a product it acquired through its 2018 takeover of Monsanto. Shareholders have also cited a lack of market trust in its top management.